

August 28, 2019

The BSE Limited

Phiroze Jeejeebhoy Towers Dalal Street

Mumbai 400 001, India

Scrip Code: 506690

The National Stock Exchange of India Limited

Exchange Plaza, Plot no. C/1, G Block Bandra-Kurla Complex

Bandra (East)

Mumbai - 400 051, India

Symbol: UNICHEMLAB

Dear Sir,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg.

For Unichem Laboratories Limited

Pradeep Bhandari

Head- Legal & Company Secretary

MUMBAI (61) (400 102) (92)



# Mumbai, Wednesday, August 28, 2019

### PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from USFDA for Solifenacin Succinate Tablets, 5 mg and 10 mg to market a generic version of Vesicare® Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc. which are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

The Product will be commercialized from Unichem's Goa plant.

## **About Unichem Laboratories Limited**

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at <a href="https://www.unichemlabs.com">www.unichemlabs.com</a>

### For more information please contact:

Mr. Pradeep Bhandari Ph: +91-22-66888 404

pradeep.bhandari@unichemlabs.com

#### Disclaimer:

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.



